Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03719612 · ClinicalTrials.gov registry record · Phase 3
DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY
A Phase 3 study, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT03719612 is a Phase 3 study that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 160 participants.
The verdict
NCT03719612, a Phase 3 study, has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as the truth standard.
Interventions
- DRUG DEFINITY®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-12-28 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03719612
The ClinicalTrials.gov registry entry for NCT03719612 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DEFINITY® is the first listed.
NCT03719612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03719612 about?
NCT03719612 is a clinical study titled "DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY". This is a Phase 3, prospective, open-label, multicenter study to evaluate Left Ventricular Ejection Fraction (LVEF) measurement accuracy and reproducibility of DEFINITY® contrast-enhanced and unenhanced echocardiography as compared with non-contrast cardiac magnetic resonance imaging (CMR) used as t...
What is the current status of trial NCT03719612?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2018-12-28. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT03719612?
The interventions under investigation include: DEFINITY® (DRUG).
Who is sponsoring clinical trial NCT03719612?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.